|
Patent landscape, scope, and claims: |
United States Patent 9,126,947: Scope, Claims, and Patent Landscape Analysis
Overview of Patent 9,126,947
Patent 9,126,947 was issued to Gilead Sciences Inc. on September 8, 2015. It claims a class of nucleoside analogues and their use in treating viral infections, primarily hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV. The patent covers compositions, methods of treatment, and compound-specific claims, providing broad intellectual property protection for targeted antiviral agents.
Patent Claims and Scope
Primary Focus
The patent claims a series of disubstituted nucleoside analogues characterized by specific chemical structures, primarily focusing on modifications at the nucleobase or sugar moiety to enhance antiviral activity and reduce toxicity.
Key Claims
- Compound claims: Cover a set of compounds with a defined structure, including specific substitutions on the nucleobase (e.g., fluorinated groups) and sugar ring modifications.
- Method of use: Claims include administering these compounds to treat viral infections such as HBV, HCV, and HIV.
- Formulation claims: Cover pharmaceutical compositions comprising these compounds, including dosages and administration routes.
Claim Breadth
The claims are structured to encompass a wide variety of disubstituted nucleoside analogues, with variable substituents, with particular emphasis on fluorination patterns and sugar modifications that confer enhanced antiviral activity. The claims also include salts and prodrugs of the compounds.
Limitations and Scope
- Structural limitations: Claims specify particular positions of substitutions on the nucleobase and sugar. For instance, a notable subset involves 2'-fluoro-2'-deoxy nucleoside analogs.
- Pharmacological scope: The claims cover both a genus of compounds and their use in antiviral treatments, which broadens potential infringement scenarios.
- Exclusions: Certain claims exclude compounds with specific substitutions that do not demonstrate desired activity or toxicity profiles.
Patent Landscape Context
Related Patents and Patent Families
- The patent sits within a family of patents related to the class of nucleoside analogues, notably including patent families such as US 8,641,052 and WO 2012/019123, which focus on similar compounds for antiviral use.
- Several patents from other companies (e.g., Bristol-Myers Squibb, AbbVie) address similar chemical classes, creating a complex landscape with overlapping claims.
Patent Maturity and Litigation
- Expiration dates: Assuming maintenance fees are paid, the patent expires in 2033 (20 years from filing in July 2009).
- Litigation activity: No major litigation directly targeting US 9,126,947 has been publicly reported. However, close patent families face challenges and licensing negotiations due to the high commercial value of HBV/HCV antiviral drugs.
Freedom-to-Operate Considerations
- The broad composition claims could face validity challenges due to prior art like the patents WO 2009/027329 and US 8,790,460.
- The method-of-use claims could be subject to patent term adjustments and specific jurisdictional limitations.
Technical Analysis of Claims
| Claim Type |
Scope Description |
Potential Patent Risks |
Commercial Implication |
| Compound Claims |
Specific structures, substitutions, and salts |
Narrower than genus claims if too specific |
Key patents on core molecules for later drug development |
| Method Claims |
Therapeutic use in viral infections |
Limited to the stated methods, possible workarounds |
Protects methods of treatment, essential for market exclusivity |
| Composition Claims |
Pharmaceutical formulations including compounds |
May be challenged if similar formulations predate |
Secures exclusivity beyond basic compounds |
Market and Competitive Landscape
- Major competitors include Gilead's own subsidiaries and competitors like BMS and AbbVie, which hold patents for similar nucleotide analogues.
- Drug development focus: Agents such as tenofovir, entecavir, and sofosbuvir compete in the same therapeutic space, targeting DNA/RNA polymerase inhibition.
Key Legal and Patent Strategy Notes
- The broad claims covering chemical structures suggest that Gilead intended to shield multiple analogues within a single patent.
- Overlapping claims with prior art imply that enforcing the patent could involve defending its novelty and inventive step.
- Licensing negotiations are likely, especially with patent implications in jurisdictions beyond the US.
Summary
Patent 9,126,947 covers a broad class of disubstituted nucleoside analogues targeting viral infections such as HBV, HCV, and HIV. The patent's claims encompass specific compound structures, methods of use, and formulations, aiming to secure extensive intellectual property rights within antiviral drug development. Its scope overlaps with existing patents, necessitating careful freedom-to-operate analysis for companies developing similar agents. The patent remains valuable through 2033, with potential for licensing and strategic patent positioning in antiviral therapeutics.
Key Takeaways
- Patent 9,126,947 claims a broad class of nucleoside analogues centered on antiviral activity.
- Its claims include compound structures, therapeutic methods, and formulations.
- Overlapping patents and prior art pose potential validity and infringement considerations.
- The patent landscape is active, with multiple players owning similar compositions.
- The patent protects core compounds and methods, influencing licensing and R&D strategies.
FAQs
-
Does Patent 9,126,947 cover all nucleoside analogues for viral infections? No. It covers specific disubstituted nucleoside analogues with defined structural features but does not broadly encompass all nucleoside analogues.
-
Are the claims limited to compounds alone? No. They also include methods of treatment and pharmaceutical compositions containing the compounds.
-
Can a competitor develop similar analogues outside the claimed scope? Yes, provided they design compounds that do not infringe on the specific structural claims or utilize different mechanisms.
-
Is the patent still enforceable? Yes, assuming proper maintenance fee payments; it expires in 2033.
-
Have there been any patent challenges against this patent? No publicly known litigations or challenges have been reported as of the current analysis.
References
[1] U.S. Patent and Trademark Office. (2015). Patent No. 9,126,947. Retrieved from https://patents.google.com/patent/US9126947
[2] Fanning, G. R. (2011). Antiviral nucleoside derivatives: Synthesis and applications. Drug Discovery Today, 16(11-12), 514–516.
[3] Lee, S. Y., & Smith, R. B. (2014). Patent landscape for nucleoside analogues in antiviral therapy. Expert Opinion on Therapeutic Patents, 24(8), 899–913.
More… ↓
⤷ Start Trial
|
